Condition: Merkel Cell Carcinoma · Sponsor: Abramson Cancer Center at Penn Medicine
The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.
This description comes directly from the study's public registry record.
Lydia Giles, BSN, RN · 2156626389 · Lydia.Giles@pennmedicine.upenn.edu
John Miura, MD · 267-588-9179 · John.Miura@Pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Penn Medicine | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05496036